American Journal of Tropical Medicine and Hygiene · 2020 · 20 citations · 30 references
PharmacyInfectious DiseasesPharmacologyClinical PharmacologyInfectious Disease PharmacotherapyPharmacovigilanceAntiparasitic ChemotherapyAntiparasitic PharmacologyAntiparasitic PharmacotherapyAntiparasitic TherapyMalariaTropical MedicineAntimalarial ChemotherapyChemotherapy Of MalariaEligible PersonsMalaria ParasitesPlasmodium FalciparumPlasmodium VivaxPrimary Efficacy EndpointsTreatment Of Malaria
Four single-arm, prospective, clinical studies of pyronaridine-artesunate efficacy in uncomplicated Plasmodium falciparum or Plasmodium vivax malaria were conducted in Myanmar between 2017 and 2019. Eligible subjects were aged at least 6 years, with microscopically confirmed P. falciparum (n = 196) or P. vivax mono-infection (n = 206). Patients received pyronaridine-artesunate once daily for 3 days with follow-up until day 42 for P. falciparum or day 28 for P. vivax. For the primary efficacy analysis, adequate clinical and parasitological response (ACPR) in the per-protocol population at day 42 for P. falciparum malaria was 100% (88/88; 95% CI: 95.9, 100) in northern Myanmar (Kachin State and northern Shan State), and 100% (101/101; 95% CI: 96.4, 100) in southern Myanmar (Tanintharyi Region and Kayin State). Plasmodium falciparum day-3 parasite clearance was observed for 96.9% (190/196) of patients. Mutations in the P. falciparum Kelch propeller domain (K13) were detected in 39.0% (69/177) of isolates: F446I (14.7% [26/177]), R561H (13.0% [23/177]), C580Y (10.2% [18/177]), and P574L (1.1% [2/177]). For P. vivax, the day-28 ACPR was 100% (104/104; 95% CI: 96.5, 100) in northern Myanmar and 100% (97/97; 95% CI: 96.3, 100) in southern Myanmar. Across both P. vivax studies, 100% (206/206) of patients had day-3 parasite clearance. There were no adverse events. Pyronaridineartesunate had excellent efficacy in Myanmar against P. falciparum and P. vivax and was well tolerated. This study supports the inclusion of pyronaridine-artesunate in national malaria treatment guidelines for Myanmar.
30
A molecular marker of artemisinin-resistant Plasmodium falciparum malaria
Frédéric Ariey, Benoît Witkowski, Chanaki Amaratunga et al. · Nature · 2013 · 2.2K citations · Full text
A Worldwide Map of<i>Plasmodium falciparum</i>K13-Propeller Polymorphisms
Didier Ménard, Nimol Khim, Johann Beghain et al. · New England Journal of Medicine · 2016 · 573 citations · Full text
Kyaw Myo Tun, Mallika Imwong, Khin Maung Lwin et al. · The Lancet Infectious Diseases · 2015 · 431 citations · Full text
Veterinary Medicine, Infectious Diseases, Molecular Genetics +17